by Portfolio Grader | May 24, 2013 10:05 am
This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
VIVUS Inc.’s (NASDAQ:VVUS) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. As of May 24, 2013, 26.2% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
Cempra Holdings LLC (NASDAQ:CEMP) experiences a ratings drop this week, going from last week’s C to a D. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CEMP, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics (NASDAQ:CORT) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of CORT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/05/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-8/
Short URL: http://investorplace.com/?p=352518
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.